To further estimate the effectiveness of HOXC6 as a biomarker for CRC, we examined the AUC values in the ROC curve for OS, DSS, and PFI at 1, 3, and 5 years (Fig. 3A–C). This evidence concerns the gene HOXC6 and colorectal carcinoma.